Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomised controlled OPERA trial

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Dženan Mašić, Syddansk Universitet
  • ,
  • Kristian Stengaard-Pedersen
  • Brian Bridal Løgstrup
  • Kim Hørslev-Petersen, King Christian 10th Hospital for Rheumatic Diseases, Syddansk Universitet
  • ,
  • Merete Lund Hetland, Rigshospitalet, Københavns Universitet
  • ,
  • Peter Junker, Odense Universitetshospital
  • ,
  • Mikkel Østergaard, Rigshospitalet, Københavns Universitet
  • ,
  • Christian Ammitzbøll
  • ,
  • Sören Möller, Syddansk Universitet, Odense Universitetshospital
  • ,
  • Robin Christensen, Odense Universitetshospital, Bispebjerg and Frederiksberg Hospital
  • ,
  • Torkell Ellingsen, Odense Universitetshospital

To compare changes in low-density lipoprotein cholesterol and other lipids in patients with rheumatoid arthritis (RA) randomised to a 1-year treat-to-target strategy with either adalimumab plus methotrexate or placebo plus methotrexate. Prespecified secondary analyses from the OPERA trial, where 180 early and treatment-naïve RA patients received methotrexate 20 mg once weekly in combination with either placebo or subcutaneous adalimumab 40 mg every other week. Serum lipid levels were measured at baseline and after 1 year. Changes in lipid levels were analysed using mixed linear models based on the intention-to-treat (ITT) population. Overall, 174 patients were included in the ITT population (adalimumab plus methotrexate n = 86; placebo plus methotrexate n = 88). Differences between changes in lipid levels were low-density lipoprotein cholesterol 0.18 mmol/l [95% CI − 0.05 to 0.42], total cholesterol 0.27 mmol/l [− 0.002 to 0.54], high-density lipoprotein cholesterol 0.05 mmol/l [− 0.06 to 0.15], triglycerides 0.11 mmol/l [− 0.08 to 0.29], very-low-density lipoprotein cholesterol 0.03 mmol/l [− 0.05 to 0.12], and non-high-density lipoprotein cholesterol 0.22 mmol/l [− 0.02 to 0.46]. In early RA patients treated to tight control of inflammation over a period of 1 year with either adalimumab plus methotrexate or placebo plus methotrexate, changes in lipid levels were similar. Trial registration number: NCT00660647.

OriginalsprogEngelsk
TidsskriftRheumatology International
Vol/bind41
Nummer3
Sider (fra-til)543-549
Antal sider7
ISSN0172-8172
DOI
StatusUdgivet - mar. 2021

Se relationer på Aarhus Universitet Citationsformater

ID: 212765281